Ipsen S.A.
IPSEF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.33B
Close$
$231.22
104.4% upside
Current Fair Value
104.4% upsideUndervalued by 104.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $9.33 Billion |
|---|---|
| Enterprise Value | $8.32 Billion |
| Annual dividend | $1.86 |
| Dividend yield | 1.06% |
| Earnings per Share | $5.32 |
| Beta | 0.32 |
| Outstanding Shares | 82,434,000 |
Return
| Return on Equity | 20.38% |
|---|---|
| Return on Assets | 12.87% |
| Return on Invested Capital | 31.12% |
Valuation & Multiples
| P/E Ratio | 24.39 |
|---|---|
| PEG | 117.88 |
| Price to Sales | 1.19 |
| Price to Book Ratio | 1.98 |
| Enterprise Value to Revenue | 1.05 |
| Enterprise Value to EBIT | 4.67 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$7.42
Consensus analyst estimateRevenue Estimate
$2.42 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 11, 2027
EPS Estimate
$8.76
Consensus analyst estimateRevenue Estimate
$2.63 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Ipsen S.A.
5,535 employees
CEO: David G. Loew
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and ac...